177Lu-labeled somatostatin receptor targeting peptide (Lutathera) has been approved for treatment of neuroendocrine tumors [13], and a 177Lu-labeled small molecule binding to PSMA is currently in advanced stage clinical trials for treatment of metastatic prostate cancer [14]. Here, FOLH1 is linked to metastatic prostate carcinoma.